TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic, serologic or clinical evidence of germ cell tumor.~* Patients scheduled to receive a 5 day fractionated cisplatin-based combination chemotherapy on permitted regimens~* Prior chemotherapy is allowed. Patients will be stratified based on previous treatment.~* Male patients 15 years of age or older at time of registration.~* Patient will provide written informed consent and authorization to release personal health information.~Exclusion Criteria:~* No known history of anticipatory nausea or vomiting.~* No use of another antiemetic agent within 72 hours prior to beginning chemotherapy.~* No known central nervous system (CNS) metastasis.~* No known hypersensitivity to any component of study regimen.~* No concurrent participation in a clinical trial which involves another investigational agent.~* No use of warfarin while on study.~* No use of agents expected to induce the metabolism of aprepitant which include: Rifampin, Rifabutin, Phenytoin, Carbamazepine, and barbiturates.~* No use of agents which may impair metabolism of aprepitant which include: Cisapride, macrolide antibiotics (Erythromycin, Clarithromycin, Azithromycin), azole antifungal agents (Ketoconazole, Itraconazole, Voriconazole, Fluconazole), Amifostine, Nelfinavir and Ritonavir.

- Gender: MALE
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Aprepitant, Then Placebo (Type: EXPERIMENTAL): Participants first received Aprepitant 125mg PO day 3 then 80mg on days 4 and 7 during study cycle 1, then received matched placebo PO daily on days 3 through 7 during study cycle 2
- Arm B: Placebo, Then Aprepitant (Type: EXPERIMENTAL): Participants first received matched placebo PO daily on days 3 through 7 during study cycle 1, then received Aprepitant 125mg PO day 3 then 80mg on days 4 and 7 during study cycle 2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Oral Famciclovir Versus Aciclovir Treatment in Patients With Herpes Zoster

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be able to understand the study procedures, agree to participate and give written consent.~* Patients with clinical diagnosis of Herpes Zoster;~* Score higher than 4 for at least for 2 symptoms of Herpes Zoster;~* Negative pregnant urine test~Exclusion Criteria:~* Pregnancy or risk of pregnancy.~* Lactation~* Any pathology or past medical condition that can interfere with this protocol.~* Non-steroidal anti-inflammatory drug , hormonal anti-inflammatory or immunosuppressive drugs (in the last 30 days and during the study);~* Patients with immunodeficiency and/or immunosuppressive disease;~* Hypersensitivity to components of the formula;~* Other conditions deemed reasonable by the medical investigator as to the disqualification of the individual from study participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Famciclovir 500mg (Type: EXPERIMENTAL): 1 tablet each 8 hours for 7 days
- Aciclovir 400mg (Type: ACTIVE_COMPARATOR): 2 tablets of Aciclovir 400 mg each 4 hours for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Previous participation in the TMC114-C202 or TMC114-C213 trials~* Significant virologic failure during participation in the above trials~* Study participation in the treatment phase of the original trial for a total of at least 12 weeks before TMC114-C215 screening~* Patient agrees to take TMC114/RTV with at least 2 other antiretrovirals (NRTIs), with or without T-20, from baseline onwards~* Patient has given informed consent~Exclusion Criteria:~* Use of disallowed concomitant therapy~* Patient with clinical or laboratory evidence of active liver disease, liver impairment/ dysfunction or cirrhosis irrespective of liver enzyme levels~* Any active or unstable medical condition that, in the investigator's opinion, would compromise the subject's safety~* Patient with laboratory abnormalities at screening as defined by ACTG grading scheme as listed in the protocol~* Patient withdrawing consent from TMC114-C202 or TMC114-C213

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): TMC114600/100 mg tablets of TMC114/rtv BID for 144 weeks or until commercial available

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combined Behavioral and Pharmacologic Treatment of Polydrug Abuse

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Opioid dependence; cocaine use~Exclusion Criteria:~* Medical or psychiatric conditions that would contraindicate participation in a methadone maintenance study; inability to give informed consent; inability to attend clinic seven days a week

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Letrozole vs Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovarian Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women age between 18-40 years.~* Normal husband semen analysis.~Exclusion Criteria:~* All infertile couples who had other causes of infertility than PCOS.~* Those who had recently taken these medications.~* Any contraindication to use of drugs e.g renal or hepatic dysfunction, hypersensitivity to this drug.~* BMI\>35 because obese women respond poorly to ovulation induction.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- letrozole (Type: EXPERIMENTAL): Patients were given letrozole 2.5 mg-7.5mg per day for 5 days started from 2nd day of menses.
- Clomiphene citrate (Type: ACTIVE_COMPARATOR): Patients were given clomiphene citrate 50-150mg per day for 5 days started from 2nd day of the menses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. A diagnosis of dyslipidemia (non-HDL-C \>130 mg/dL and Triglycerides \> or equal to 150 mg/dL and \< or equal to 500 mg/dL).~2. Subject may be currently on a statin or other lipid-lowering therapy but must be willing and able to washout for 8 weeks if on a fibrate or high-dose niacin, 6 weeks if on a statin or low-dose niacin per day, or 4 weeks if on a bile acid sequestrant, ezetimibe, or \>1000 mg of fish oil per day.~3. Other inclusion criteria might apply~Exclusion Criteria:~1. TGs \> 500 mg/dL.~2. History of coronary heart disease (CHD), transient ischemic attacks, stroke or revascularization procedure in the six months prior.~3. Presence of an aortic aneurysm or resection of an aortic aneurysm within six months.~4. Poorly controlled diabetes mellitus (glycosylated hemoglobin \>8.0% )or diabetes mellitus requiring insulin therapy.~5. Known lipoprotein lipase impairment or deficiency or Apo C-II deficiency or familial dysbetalipoproteinemia.~6. History of pancreatitis.~7. Known allergy or sensitivity to statins or fibrates.~8. Poorly controlled hypertension.~9. Other exclusion criteria might apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LCP-AtorFen (Type: EXPERIMENTAL): LCP-AtorFen 40/100mg fixed-dose combination tablet of 40mg atorvastatin and 145mg fenofibrate for treatment of mixed dyslipidemia
- atorvastatin (Type: ACTIVE_COMPARATOR): atorvastatin 40mg tablet (Lipitor), as an adjunct to diet and exercise for treatment of mixed dyslipidemia
- fenofibrate (Type: ACTIVE_COMPARATOR): fenofibrate 145mg tablet (Tricor), as an adjunct to diet and exercise for treatment of mixed dyslipidemia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Once Monthly Subcutaneous Mircera in Dialysis Patients With Chronic Renal Anemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients \>=18 years of age;~* chronic renal anemia;~* regular long-term hemodialysis or peritoneal dialysis, with same mode of dialysis for \>=3 months;~* continuous iv maintenance epoetin alfa therapy with same dosing interval during previous 2 months.~Exclusion Criteria:~* transfusion of red blood cells during previous 2 months;~* poorly controlled hypertension;~* significant acute or chronic bleeding;~* active malignant disease (except non-melanoma skin cancer).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- C.E.R.A. (Type: EXPERIMENTAL): Eligible participants will be administered continuous erythropoietin receptor activator (C.E.R.A.\[Mircera\]) intravenously (IV) every 4 weeks for 44 weeks. The starting dose of 120, 200, or 360 micrograms (mcg) will be based on the dose of epoetin alfa or beta administered in the week preceding the switch to C.E.R.A. Subsequent doses will be adjusted to maintain the individual participant's hemoglobin (Hb) within a range of +/- 1.0 grams per deciliter (g/dL) of the reference hemoglobin (Hb) concentration and between 10.50 and 12.50 g/dL.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Key Inclusion Criteria:~* Males and non-pregnant, non-lactating females between 18 - 80 years of age inclusive, based on the date of the screening visit.~* Main Study only: Body mass index (BMI) \> 25 kg/m\^2 (unless the patient has biopsy-proven NASH documented within the last 2 years).~* Main Study only: Must have confirmation of ≥ 10% liver fat content on magnetic resonance imaging- proton density fat fraction (MRI-PDFF) at screening.~* Main Study only: Biopsy-proven NASH. Must have had a liver biopsy within 180 days of randomization with fibrosis stage 1 to 3 and a non-alcoholic fatty liver disease (NAFLD) activity score (NAS) of ≥ 4 with at least a score of 1 in each of the following NAS components:~  * Steatosis (scored 0 to 3),~ * Ballooning degeneration (scored 0 to 2), and~ * Lobular inflammation (scored 0 to 3)~* Cohort C only: FibroScan® measurement \> 13.1 kPa.~* Cohort C only: Cirrhosis due to NASH. Liver biopsy consistent with F4 fibrosis according to the NAS system, confirmed by the central or local reader.~Exclusion Criteria:~* Weight gain or loss \> 5% in the 3 months prior to randomization or \> 10% in the 6 months prior to screening.~* Type 1 and insulin-dependent Type 2 diabetes.~* Poorly controlled hypertension (blood pressure \> 160/100).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- EFX Dose 1 (Type: EXPERIMENTAL): Main Study
- EFX Dose 2 (Type: EXPERIMENTAL): Main Study
- EFX Dose 3 (Type: EXPERIMENTAL): Main Study
- Placebo (Type: PLACEBO_COMPARATOR): Main Study
- EFX Dose (Cohort C) (Type: EXPERIMENTAL): None
- Placebo (Cohort C) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Distal Renal Denervation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* systolic BP is equal or greater than 160 mmHg or diastolic BP is equal or greater than 100 mmHg,~* stable (\>3 months) treatment with full doses of at least 3 antihypertensive drugs including a diuretic,~* given written informed consent~Exclusion Criteria:~* secondary hypertension~* 24h-mean systolic BP \<135 mmHg,~* estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m2,~* extended disease of renal artery,~* any other clinically important disorders/comorbidities significantly increasing risk of endovascular intervention (investigator's assessment)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Distal renal denervation (Type: EXPERIMENTAL): Endovascular denervation of segmental branches of renal artery
- Conventional renal denervation (Type: ACTIVE_COMPARATOR): Endovascular denervation of main trunk of renal artery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: This Study is An Open-Label Trial Of Pregabalin In Patients With Fibromyalgia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have met the inclusion criteria for the preceding fibromyalgia Protocol A0081100, and must have received pregabalin/placebo under double-blind conditions.~Exclusion Criteria:~* Patients may not participate in the study if they experienced a serious adverse event during the previous fibromyalgia Study A0081100 which was determined to be related to the study medication by the investigator or the sponsor.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Previously untreated AML and high-risk MDS ( \> 10% blasts, or International Prognostic Scoring System (IPSS) intermediate-2). Prior therapy with hydroxyurea, single agent chemotherapy (e.g. decitabine), hematopoietic growth factors, biological or targeted therapies are allowed.~* Age \> 60 years.~* Eastern Cooperative Oncology Group (ECOG) performance status \</= 2.~* Sign a written informed consent form.~* Adequate liver function (total bilirubin \< 2mg/dL,serum glutamic pyruvic transaminase (SGPT) or Serum glutamic oxaloacetic transaminase (SGOT) \< x 4 upper limit of normal (ULN)) and renal function (serum creatinine \< 2mg/dL).~Exclusion Criteria:~* Patients with \>= New York Heart Association (NYHA) grade 3 heart disease as assessed by history and/or physical examination.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clofarabine (Type: ACTIVE_COMPARATOR): Clofarabine intravenous (IV) 30 mg/m\^2 daily times 5 days
- Clofarabine Plus Ara-C (Type: ACTIVE_COMPARATOR): Clofarabine IV 30 mg/m\^2 daily times 5 days + Ara-C 20 mg/m\^2 subcutaneously daily times 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Heart Rate Control With Esmolol in Septic Shock

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* septic shock criteria~* presence of heart rate \> 95 bpm.~Exclusion Criteria:~* Pregnancy~* age \< 18

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- esmolol (Type: EXPERIMENTAL): None
- control (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Aripiprazole in Trichotillomania

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Eligible patients:~* Must be outpatients between the ages of 18 and 65 at the start of study~* May be male or female~* Have DSM-IV trichotillomania of at least 6 months duration~* Allowed psychotropic medications are limited to:~  * SSRIs (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline), SNRIs (duloxetine, venlafaxine) and mirtazapine, as long as the dosage has not changed for 4 weeks prior to study enrollment.~ * Other allowed medications include non-hypnotic sleeping agents, specifically trazodone, diphenhydramine, hydoxyzine and ramelteon.~ * If a patient is taking non-allowed psychotropic medications, he/she must be titrated off by the prescribing physician and be off of the medication for at least 2 weeks prior to trial enrollment.~* We will not exclude patients meeting DSM-IV criteria for:~  * body dysmorphic disorder;~ * major depression;~ * dysthymia;~ * GAD, social phobia, panic disorder.~Exclusion Criteria:~* We will exclude patients suffering from:~  * organic mental disorders;~ * psychotic mental disorders including delusional disorder, somatic type;~ * mental retardation or developmental disabilities;~ * substance or alcohol abuse;~ * depressive disorders with current suicidal risk;~ * factitious disorders;~ * dissociative disorders;~ * obsessive compulsive disorder;~ * personality disorders sufficiently severe to interfere with cooperation with the study;~ * bipolar I or II disorder.~* Patients taking psychotropic agents other than those specifically listed in item d above. If a patient is taking non-allowed psychotropic medications, he/she must be titrated off such medications by the prescribing physician and be off of the medication for 2 weeks prior to trial enrollment.~* Pregnant or nursing women.~* Patients with a known hypersensitivity or allergy to aripiprazole.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Open-label aripiprazol (Type: EXPERIMENTAL): Aripiprazole dose of 5 mg/d, which could be reduced to 2 mg/d if the initial dose was not tolerated. Dose was increased by up to 5 mg at intervals of 2 weeks until a maximum target dosage of 15 mg/d was reached at the beginning of week 5. Dose was not increased if the subject showed clinical improvement at a lower dose, defined as a 50% reduction in Massachusetts General Hospital Hair Pulling Scale (MGHHPS), or was intolerant of a further dosing increase. Dose was not increased after week 5; at any point, it could be decreased secondary to side effects.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reducing Adverse Self-Medication Behaviors in Older Adults With Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria for Older Adults:~* Older adult diagnosed with hypertension~* Health literacy score (REALM) of 44 or greater~* Independent physical and cognitive functioning~* Visual acuity of at least 20/100, with corrective lenses~Exclusion criteria for Older Adults:~* less than age 60~* health literacy score below 44 (6th grade)~* not currently prescribed antihypertensive medication~* visual acuity of less than 20/100 (with corrective lenses, if needed)~* inability to meet independent-living and cognitive-functioning ability.~Inclusion Criteria for APRNs:~* Affiliated with ProHealth Physicians, Inc. practice site in CT and/or~* Affiliated with APRN practice sites in CT~Exclusion Criteria for APRNs:~* Not affiliated with primary care practice sites in CT

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Education (Type: EXPERIMENTAL): PEP-NG targeted and tailored education intervention
- Control (Type: OTHER): Control, intervention is care as usual.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete